Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials

Bibliography

• National Diabetes Information Clearinghouse. Deaths among people with diabetes, United States, 2002. Available from: http://diabetes.niddk.nih.gov/dm/pubs/statistics/#12. [Accessed 7 September 2007]
   Google Scholar
• Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14(Suppl 5):S1-85
   PubMedGoogle Scholar
• Boulton AJ, Vinik AI, Arezzo JC, Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28(4):956-62
   PubMed Web of Science ®Google Scholar
• Schmader KE. Epidemiology and impact on quality of life of post therapeutic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18(6):350-4
   PubMed Web of Science ®Google Scholar
• Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004;27(6):1458-86
   PubMed Web of Science ®Google Scholar
• Zelman DC, Brandenburg NA, Gore M. Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain 2006;22(8):681-5
   PubMed Web of Science ®Google Scholar
• Argoff CE, Backonja MM, Belgrade MJ, Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc 2006;81(4 Suppl):S12-25
   PubMedGoogle Scholar
• Gore M, Brandenburg NA, Hoffman DL, Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain 2006;7(12):892-900
   PubMed Web of Science ®Google Scholar
• Tolle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications 2006;20(1):26-33
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Woehl A, The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia 2006;49(10):2272-80
   PubMed Web of Science ®Google Scholar
• Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc 2006;81(4 Suppl):S3-11
   PubMed Web of Science ®Google Scholar
• Basbaum I, Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 1984;7:309-38
   PubMed Web of Science ®Google Scholar
• Clark FM, Proudfit HK. The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: anatomical evidence that A5 neurons modulate nociception. Brain Res 1993;616(1-2):200-10
   PubMed Web of Science ®Google Scholar
• Coderre TJ, Katz J. Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. Behav Brain Sci 1997;20(3):404-19
   PubMed Web of Science ®Google Scholar
• Iyengar S, Webster AA, Hemrick-Luecke SK, Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004;311(2):576-84
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116(1-2):109-18
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Gahimer J, Yalcin I, Safety and adverse event profile of duloxetine. Expert Opin Drug Saf 2005;4(6):987-93
   PubMedGoogle Scholar
• Raskin J, Pritchett YL, Wang F, A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6(5):346-56
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Raskin J, Rosen A, Duloxetine in the long-term management of diabetic peripheral neuropathic pain: an open-label, 52-week extension of a randomized controlled clinical trial. Curr Ther Res 2006;67(5):283-304
   PubMed Web of Science ®Google Scholar
• Raskin J, Smith TR, Wong K, Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med 2006;9(1):29-40
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Pritchett YL, D'souza DN, A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67(8):1411-20
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Wang F, Pritchett YL, An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med 2007;8(6):503-13
   PubMed Web of Science ®Google Scholar
• Feldman EL, Stevens MJ. Clinical testing in diabetic peripheral neuropathy. Can J Neurol Sci 1994;21(4):S3-7
   PubMed Web of Science ®Google Scholar
• Acharya N, Rosen AS, Polzer JP, Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol 2006;26(6):587-94
   PubMed Web of Science ®Google Scholar
• Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999;20(3):277-87
   PubMed Web of Science ®Google Scholar
• Gahimer J, Wernicke J, Yalcin I, A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007;23(1):175-84
   PubMedGoogle Scholar
• Robinson M, Shen S, Gonzales J, Duloxetine in the management of DPNP: temporal profile of treatment emergent adverse events. Presented at the 58th Annual Meeting of the American Academy of Neurology;San Diego; CA, USA; 2006
   Google Scholar
• Dunner D, Kornstein S, Whitmyer V, Effects of initial dosing strategies of duloxetine on tolerability and efficacy in patients with major depressive disorder. Presented at the 45th Annual Meeting of the American College of Neuropsychopharmacology; Hollywood, FL, USA; 2006
   Google Scholar
• Wernicke J, Lledo A, Raskin J, An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007;30(5):437-55
   PubMed Web of Science ®Google Scholar
• Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001;24(13):969-78
   PubMed Web of Science ®Google Scholar
• Hardy T, Sachson R, Shen S, Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007;30(1):21-6
   PubMed Web of Science ®Google Scholar
• Data on file: Lilly Research Laboratories (1992)
   Google Scholar
• Data on file: Lilly Research Laboratories (1990)
   Google Scholar
• Data on file: Lilly Research Laboratories (1989)
   Google Scholar
• Wernike J, Pangallo B, Wang F, Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr Drug Saf 2008;3:132-42
   PubMedGoogle Scholar
• Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck depression inventory: twenty-five years of evaluation. Clin Psychol Rev 1988;8:77-100
   Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar